Cellivery Announces Anti-Inflammatory Drug Efficacy for Autoimmune Disease Psoriasis at JP Morgan Conference

In the autoimmune disease psoriasis model, excessive inflammatory responses cause abnormal collapse and sclerosis of the stratum corneum, resulting in irregularly damaged skin tissue (left), which is normalized by iCP-NI (right).

[Asia Economy Reporter Eunmo Koo] Cellivery announced on the 14th that it presented recent research results on the autoimmune disease psoriasis treatment ‘iCP-NI’ at the 2021 JP Morgan Healthcare Conference.

iCP-NI is an anti-inflammatory immune therapeutic drug that has already been developed as an innate immune regulatory treatment for novel coronavirus infection (COVID-19) and is preparing for clinical trials in the United States. Psoriasis occurs when T cells, a type of immune cell, become abnormally activated, secreting various pro-inflammatory substances that cause excessive proliferation of skin keratinocytes. It is an autoimmune disease with no current cure and recurs throughout a patient’s lifetime.

The head of Cellivery’s autoimmune disease research stated, “iCP-NI reduced the infiltration of inflammation-inducing immune cells (T cells) into skin tissue by 80%, and decreased the levels of severe pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-22 (IL-22) by 66% and 90%, respectively, demonstrating strong anti-inflammatory and anti-psoriatic therapeutic effects.” He added, “The thickness of the hardened and irregularly sliced epidermis and dermis, thickened due to persistent inflammatory responses, was reduced by 82% and 85%, respectively, restoring the skin tissue.”

Cellivery plans to develop iCP-NI as an ointment drug. To this end, it has signed a production contract with Eurofins, a global ointment and cream contract development and manufacturing organization (CDMO) based in Luxembourg, and is promoting joint formulation development.

This content was produced with the assistance of AI translation services.